Peer-reviewed studyPNAS
Lab study finds malaria drug lumefantrine slows hematin crystal growth
A peer-reviewed study combining parasite experiments with laboratory and microscopy work examines how lumefantrine, one of the drugs in current malaria combination therapies, acts on hematin crystallization, a process malaria parasites rely on to survive. The authors report that lumefantrine suppresses Plasmodium falciparum parasites in their assays and slows hematin crystal growth, while also promoting the formation of hematin-rich clusters.
- Published
- Oct 12, 2026
DOI 10.1073/pnas.2613405123
Peer-reviewed studyPLOS Medicine
Four models compare typhoid vaccine schedules across settings
A peer-reviewed multi-model comparison, commissioned by the World Health Organization (WHO), used four computer models of typhoid transmission to compare schedules for typhoid conjugate vaccine (TCV). The models predicted that routine vaccination at 9 months, with a catch-up campaign to 15 years and a booster at 5 years, would have the greatest impact, cutting cases by a median of 40% to 68% over 10 years, and that the best schedule depends on incidence, case fatality risk and how fast protection wanes.
- Published
- Oct 13, 2026
DOI 10.1371/journal.pmed.1005280
Preprint, not peer-reviewedbioRxiv
Preprint links liver protein UBE4A to fatty liver protection in mice
A preprint, not yet reviewed by other scientists, reports mouse experiments and human liver samples on UBE4A, a protein the authors say protects against fatty liver disease (MASLD) and steatohepatitis (MASH) by keeping the endoplasmic reticulum (ER) working properly. In the mice, deleting the protein in liver cells worsened fatty liver changes, inflammation and insulin resistance, and the authors say levels of the protein are lower in human MASLD and MASH livers.
- Published
- Oct 13, 2026
DOI 10.64898/2026.10.07.757434
Preprint, not peer-reviewedmedRxiv
Preprint reports BCG lowered blood sugar in a type 1 diabetes trial
A preprint, not yet reviewed by other scientists, reports a randomized, double-blind, placebo-controlled phase 2 trial of BCG, which the authors call an old generic drug, in people with type 1 diabetes (T1D), followed for up to 8 years. The authors report that hemoglobin A1c (HbA1c), a measure of average blood sugar, fell by 7.04% at year 5 and 12.84% at year 8 in the BCG group but did not change in the placebo group, and that BCG was safe.
- Published
- Oct 13, 2026
DOI 10.64898/2026.10.09.26365133
Preprint, not peer-reviewedbioRxiv
Mouse preprint suggests ovarian aging depends on the wider body
A preprint, not yet reviewed by other scientists, reports ovary transplant experiments and parabiosis experiments (where two animals share a circulation) in mice. The authors report that ovarian aging shifted in both directions depending on the host, and that ovaries from 13-month-old donors supported live births when moved into young hosts but not into old hosts.
- Published
- Oct 13, 2026
DOI 10.64898/2026.10.11.758357
Preprint, not peer-reviewedbioRxiv
Preprint links stress response in brain cells to vascular dementia in mice
A preprint, not yet reviewed by other scientists, reports that mice fed a high-fat diet and with hypertension developed oligodendroglial cell loss, thinner myelin, memory problems and features the authors say resemble vascular dementia. Blocking the integrated stress response (ISR) in those cells, or deleting the ISR-activating kinase PERK from them, protected the mice, and the authors say the pathway may be a therapeutic target.
- Published
- Oct 13, 2026
DOI 10.64898/2026.10.12.758545
Peer-reviewed studyCell
Study maps structural variants in 467,152 UK Biobank genomes
A peer-reviewed study in Cell analyzes 467,152 genomes from the UK Biobank to map structural variants, which it describes as changes in DNA sequence greater than 50 base pairs. The authors say these variants are an important and previously underrecognized source of human disease risk, and the resource reveals rare and regulatory variants linked to disease.
- Published
- Oct 15, 2026
DOI 10.1016/j.cell.2026.09.035
Preprint, not peer-reviewedbioRxiv
Preprint reports fucose sugar in HIV vaccine design broadens antibody response
A preprint, not yet reviewed by other scientists, reports HIV-1 vaccine candidates, made by human immunodeficiency virus type 1 (HIV-1) researchers, that carry a core fucose sugar on their envelope protein, tested mainly in mice. The authors say the sugar supports neutralizing antibody responses against several strains, and that humanized mice showed detectable neutralization by week 11.
- Published
- Oct 15, 2026
DOI 10.64898/2026.10.08.757767
Preprint, not peer-reviewedbioRxiv
Preprint reports llama nanobodies that bind conserved COVID-19 virus sites
A preprint, not yet reviewed by other scientists, reports single-domain antibodies, called nanobodies, isolated from a llama immunized with a mosaic receptor-binding domain (RBD) nanoparticle. The authors say some of the nanobodies bind conserved parts of the SARS-CoV-2 spike protein, the virus that causes COVID-19, and neutralized several variants of concern (VOCs) and zoonotic sarbecoviruses in tests, which they say shows potential therapeutic use.
- Published
- Oct 15, 2026
DOI 10.64898/2026.10.13.758647
Preprint, not peer-reviewedmedRxiv
Preprint estimates modest out-of-pocket costs but heavy time burden for COVID-19 care
A preprint, not yet reviewed by other scientists, reports two U.S. surveys from fall 2023, one of adults and one of caregivers of children, on costs and time spent on COVID-19 illness. The authors report median out-of-pocket medical costs per visit of $5 to $10 for adults, time spent ranging from 90 to 300 minutes across settings, and that 34% of adults reported COVID-related financial challenges.
- Published
- Oct 15, 2026
DOI 10.64898/2026.10.14.26365534
Preprint, not peer-reviewedbioRxiv
Preprint identifies bacterial enzymes that release sugar chains from lipid carrier
A preprint, not yet reviewed by other scientists, identifies three enzymes in Escherichia coli, called UprA, UprB and UprC, that release sugar-based chains from undecaprenyl, a lipid carrier that bacteria use to build their cell envelope. The authors say UprA completes the synthesis of peptidoglycan, and that this enzyme family could be a potential target for antibiotics.
- Published
- Oct 15, 2026
DOI 10.64898/2026.10.14.759067
Preprint, not peer-reviewedbioRxiv
Preprint screens tuberculosis drug target pairs for synergy
A preprint, not yet reviewed by other scientists, reports a pooled CRISPR interference (CRISPRi) screen in Mycobacterium tuberculosis that tested 1,326 pairs of 51 drug-target genes. The authors say many pairs were synergistic, and that chemically inhibiting polyketide synthase 13 (Pks13) made several antitubercular drugs more effective in lab tests.
- Published
- Oct 15, 2026
DOI 10.64898/2026.10.14.759252